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Background. We previously reported the noninferiority 1 month after the last dose of 2-dose human papillomavirus 16/18 
AS04-adjuvanted (AS04-HPV-16/18) vaccine schedules at months 0 and 6 (2D_M0,6) and months 0 and 12 (2D_M0,12) in girls 
aged 9–14 years compared with a 3-dose schedule at months 0, 1, and 6 (3D_M0,1,6) in women aged 15–25 years. Here, we report 
the results at study end (month 36 [M36]).
Methods. Girls were randomized 1:1 and received 2 vaccine doses either 6 months (2D_M0,6) or 12 months apart (2D_M0,12); 
women received 3 doses at months 0, 1, and 6 (3D_M0,1,6). Endpoints included noninferiority of HPV-16/18 antibodies for 2D_
M0,6 versus 3D_M0,1,6; 2D_M0,12 versus 3D_M0,1,6; and 2D_M0,12 versus 2D_M0,6; and assessment of neutralizing antibodies, 
T cells, B cells, and safety.
Results. At M36, the 2D_M0,6 and 2D_M0,12 schedules remained noninferior to the 3D_M0,1,6 schedule in terms of sero-
conversion rates and 3D/2D geometric mean titers for anti-HPV-16 and anti-HPV-18. All schedules elicited sustained immune 
responses up to M36.
Conclusions. Both 2-dose schedules in young girls remained noninferior to the 3-dose schedule in women up to study conclu-
sion at M36. The AS04-HPV-16/18 vaccine administered as a 2-dose schedule was immunogenic and well tolerated in young girls.
Keywords. human papillomavirus (HPV); 2-dose schedule; cervical cancer; Cervarix.
 
Cervical cancer is one of the most common cancers among 
women worldwide. Approximately 528 000 new cervical cancer 
cases and 266 000 deaths occurred in 2012 worldwide [1, 2]. 
Most human papillomavirus (HPV) infections clear naturally, 
but persistent infections lead to cervical cancer. Human papil-
lomavirus 16 and HPV-18 are the most common among high-
risk HPV types and are responsible for approximately 70% of 
cervical cancer cases [3–7]. Universal mass HPV vaccination 
began approximately 10  years ago using a 3-dose schedule, 
and prophylactic HPV vaccination programs with the AS04-
HPV-16/18 vaccine (Cervarix; GSK) and the 4-valent HPV vac-
cine (Gardasil; Merck & Co) have been shown to contribute to 
the reduction in HPV prevalence [8–13].
The initially licensed schedule for the AS04-HPV-16/18 
vaccine is comprised of 3 doses administered at months 0, 
1, and 6 (3D_M0,1,6). However, high vaccine coverage and 
compliance rates can be difficult to achieve with the 3-dose 
regimen. The high immune response to the vaccine observed 
in the younger population led to the investigation of a 2-dose 
schedule [14].
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The current phase III confirmatory study evaluated the immu-
nogenicity and safety of the AS04-HPV-16/18 vaccine admin-
istered as 2 alternative 2-dose schedules: a 2-dose schedule at 
months 0 and 6 (2D_M0,6) or a 2-dose schedule at months 0 
and 12 (2D_M0,12) in girls aged 9–14 years compared with the 
standard 3D_M0,1,6 schedule in women aged 15–25 years. We 
previously reported that both 2-dose schedules were immuno-
logically noninferior to the standard 3D_M0,1,6 schedule up 
to 13 months after the first dose.[15] Because long-term pro-
tection following HPV vaccination is important, subjects were 
followed through 36 months after vaccination. Here, we report 
study results up to 36 months after the first vaccine dose.
METHODOLOGY
Study Design and Participants
This study was a phase IIIb, multicenter, open-label, randomized 
trial (ClinicalTrials.gov NCT01381575) conducted in 5 coun-
tries (Canada, Germany, Italy, Taiwan, and Thailand) between 
2011 and 2014 [15, 16]. Healthy girls aged 9–14 years were ran-
domized (1:1) to either the 2D_M0,6 group or the 2D_M0,12 
group. Women aged 15–25 years who received the 3D_M0,1,6 
schedule served as the control group. The inclusion/exclusion 
criteria, the study population, randomization and masking, and 
vaccine composition were previously described [15].
The primary objective to demonstrate the noninferiority of the 
2D_M0,6 schedule as compared with the 3D_M0,1,6 schedule 
at month 7 was met and described previously [15]. 
Secondary objectives included evaluation of the noninferior-
ity of the reduced schedules as compared with the 3D_M0,1,6 
schedule until study conclusion at month 36 (M36), assess-
ment of anti–HPV-16/18 neutralizing antibodies (nAbs), HPV-
16/18–specific T-cell and memory B-cell responses, and safety.
The study protocol, all amendments, and informed consent 
were reviewed and approved by an independent ethics commit-
tee or institutional review board. The study was designed and 
conducted according to the principles from the Declaration 
of Helsinki, Good Clinical Practice guidelines and all other 
applicable regulatory requirements. Written informed consent 
was obtained from every participant and/or the parent/legally 
authorized representative.
Immunogenicity Assessments
Anti–HPV-16/18 antibodies were assessed in all participants by 
enzyme-linked immunosorbent assay (ELISA), with the assay 
cutoff of 8 ELISA units (EU)/mL for anti–HPV-16 and 7 EU/mL 
for anti–HPV-18 up to month 12. The assay cutoff was revised 
from month 18 onward to increase precision [15]; hence 19 
EU/mL for anti–HPV-16 and 18 EU/mL for anti–HPV-18 were 
used from month 18 to month 36.[15] Human papillomavirus 
16/18 nAbs, T cells, and B cells were determined in a subset 
of participants, as previously described [17]. Human papillo-
mavirus 16/18 nAbs were determined by pseudovirion-based 
neutralization assay (PBNA) with a cutoff of 40 estimated dose 
50% (ED50; serum dilution giving a 50% reduction of the signal 
compared with a control without serum). CD4+ and CD8+ T 
cells specific to HPV-16/18/31/45 were evaluated by intracellu-
lar cytokine staining. B-cell responses to HPV-16/18/31/45 were 
assessed by B-cell enzyme-linked immunosorbent spot assay.
Safety Assessments
The occurrence of serious adverse events (SAEs); the occurrence 
of SAEs related to the investigational product, to study partic-
ipation, to GSK concomitant products or any fatal SAE; the 
occurrence of medically significant conditions; and the occur-
rence of pregnancy and pregnancy outcomes were recorded 
throughout the study period in all groups.
Statistical Methods
The primary analyses of immunogenicity were based on the 
M36 according-to-protocol (ATP) cohort for immunogenicity 
(ATP-I); secondary immunogenicity analyses based on the M36 
total vaccinated cohort (TVC) were performed to complement 
the ATP analyses. Safety analyses were based on the TVC.
The ATP-I at M36 included all participants who met  all of 
the eligibility criteria, complied with the study procedures, and 
for whom data concerning immunogenicity endpoint measures 
were available. The TVC at M36 included all participants who 
received at least 1 dose of the study vaccine and for whom data 
were available at the follow-up visit. Noninferiority and descrip-
tive immunogenicity analyses were based on the initially sero-
negative participants in the ATP-I cohort.
Seroconversion was defined as the appearance of antibodies 
(ie, titer greater than or equal to the cutoff value) in the serum 
of subjects seronegative before vaccination. Seropositivity was 
defined as an antibody titer greater than or equal to the cut-
off value. The geometric mean titer (GMT) calculations were 
performed by taking the antilog of the mean of the log titer 
transformations. Antibody titers below the cutoff of the assay 
were given an arbitrary value of half the cutoff for the purpose 
of GMT calculation. Seroconversion and seropositivity rates for 
each antigen and GMTs were calculated with exact 95% confi-
dence intervals (CIs) before and after vaccination.
The frequencies of HPV-16/18/31/45–specific CD4+ T cells 
producing cytokines and memory B cells were summarized.
To assess the noninferiority, the following between-group com-
parisons were performed. For noninferiority in terms of serocon-
version rates, for each HPV antigen, the upper limit (UL) of the 
2-sided standardized asymptotic 95% confidence interval of the 
difference between the percentages of seroconverted subjects in 
the 3-dose schedule and the 2-dose schedule (or between the two 
2-dose schedules) was computed. If noninferiority in terms of 
seroconversion rates was reached (UL of the 2-sided standard-
ized asymptotic 95% confidence interval of the difference in the 
percentage of seroconverted subjects in both groups was <5%), 
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the 2-sided 95% confidence intervals of GMT ratios were com-
puted using an analysis of variance (ANOVA) model on the log10 
transformation of the titers at each timepoint. Noninferiority in 
terms of GMTs was demonstrated if the UL of 95% confidence 
interval for the GMT ratio for both groups was <2. The ANOVA 
model included the vaccine group as fixed effect.
Noninferiority was assessed sequentially first for the 2D_
M0,6 versus 3D_M0,1,6, and then for 2D_M0,12 versus 3D_
M0,1,6 and 2D_M0,12 versus 2D_M0,6. Noninferiority was 
tested at all timepoints, and if not reached, analysis at the subse-
quent timepoint was not performed.
The sample size was calculated to provide sufficient power 
to compare the 2D_M0,6 group with the 3D_M0,1,6 group up 
to the study end (M36). A total of 1428 subjects allowed for 
the detection of a 5% difference between the 2D_M0,6 and 
the 3D_M0,1,6 groups for seroconversion rates and a 2-fold 




A total of 1447 participants were included in the study; 1362 of 
1447 (94.1%) completed the M36 visit. A total of 1285 of 1362 
(88.8%) participants were included in the ATP-I cohort at M36 
(Figure 1). The first subject was enrolled in the study on 29 June 
2011, and the last study visit for M36 was on 13 November 2014. 
This report presents data from the follow-up visits at M36.
Due to the temporary unavailability of the allocated vac-
cine for the 2D_M0,12 group at some study sites, the ran-
domization system allocated girls to the 2D_M0,6 group at 
a higher rate. Although this led to an imbalance in terms of 
the number of participants in both 2-dose groups, no impact 
Figure 1. Flow of participants. Abbreviations: 2D_M0,6, 2-dose schedule administered at months 0 and 6; 2D_M0,12, 2-dose schedule administered at months 0 and 12; 3D_M0,1,6, 
3-dose schedule administered at months 0, 1, and 6; ATP-I, according-to-protocol cohort for immunogenicity; M, month; SAE, serious adverse event; TVC, total vaccinated cohort.
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on the validity of the study was noted because a sufficient 
number of girls were randomized to the 2D_M0,12 group to 
allow evaluation of study objectives (Table 1). Demographic 
characteristics and baseline HPV serostatus of the study par-
ticipants in the ATP-I are available in the Supplementary 
Materials.
Table 1. Demographic Characteristics and Baseline Human Papillomavirus Serostatus of the Study Participants in the Total Vaccinated Cohort
2D_M0,6 girls aged 9–14 y 2D_M0,12 girls aged 9–14 y 3D_M0,1,6 women aged 15–25 y
Patient Characteristics n = 524 n = 395 n = 443
Age, y, at time of first vaccine dose, mean (SD) 14.5 (1.6) 14.3 (1.6) 22.5 (3.1)
Geographic ancestry, no. (%)
 African heritage / African American 4 (0.8) 6 (1.5) 3 (0.7)
 Asian—Central/South Asian heritage 1 (0.2) 2 (0.5) 1 (0.2)
 Asian—East Asian heritage 139 (26.5) 71 (18.0) 104 (23.5)
 Asian—South East Asian geritage 105 (20.0) 103 (26.1) 103 (23.3)
 White—Arabic / North African heritage 1 (0.2) 1 (0.3) 0 (0.0)
 White—Caucasian / European heritage 269 (51.3) 210 (53.2) 229 (51.7)
 Other 5 (1.0) 2 (0.5) 3 (0.7)
HPV-16 baseline serostatus, no. (%)
 Seronegativea 468 (89.3) 353 (89.4) 365 (82.4)
 Seropositive 54 (10.3) 42 (10.6) 76 (17.2)
 Not available 2 (0.4) 0 (0.0) 2 (0.4)
HPV-18 baseline serostatus, no. (%)
 Seronegativea 476 (90.8) 371 (93.9) 392 (88.5)
 Seropositive 42 (8.0) 21 (5.3) 49 (11.0)
 Not available 6 (1.2) 3 (0.8) 2 (0.5)
Abbreviations: 2D_M0,6, 2-dose schedule administered at months 0 and 6; 2D_M0,12, 2-dose schedule administered at months 0 and 12; 3D_M0,1,6, three-dose schedule administered at 
months 0, 1, and 6; HPV, human papillomavirus; SD, standard deviation; TVC, total vaccinated cohort.
aSeronegative status defined as an antibody titer lower than the assay cutoff before vaccination (19 enzyme-linked immunosorbent assay units [EU]/mL for HPV-16 and 18 EU/mL for HPV-18).
Table 2. Noninferiority Assessment of Human Papillomavirus 16 and Human Papillomavirus 18 Antibody Responses in Initially Seronegative Participants 
at Month 36 (According-to-Protocol Cohort for Immunogenicity)
Antibody Group Age, y No.
Seroconversion,  
% (95% CI)




GMT ratiob,  
(95% CI)
2D_M0,6 vs 3D_M0,1,6 3D − 2D_M0,6 3D/2D_M0,6
HPV-16 2D_M0,6 9–14 455 100 (99.2–100) 1210.2 (1124.8–1302.1) 0.00 (−1.15 to 0.84) 1.10 (0.97–1.24)
3D_M0,1,6 15–25 330 100 (99.0–100) 1326.4 (1193.9–1473.5) … …
HPV-18 2D_M0,6 9-14 462 99.8 (98.8–100) 562.8 (516.4–613.4) −0.06 (−1.37 to 0.96) 0.98 (0.85–1.13)
3D_M0,1,6 15–25 356 99.8 (98.4–100) 552.6 (494.1–618.0) … …
2D_M0,12 vs 3D_M0,1,6 3D − 2D_M0,12 3D/2D_M0,12
HPV-16 2D_M0,12 9–14 339 100 (98.9–100) 1559.3 (1431.2–1699.0) 0.00 (−1.15 to 1.12) 0.85 (0.74–0.97)
3D_M0,1,6 15–25 330 100 (98.9–100) 1326.4 (1193.9–1473.5) … …
HPV-18 2D_M0,12 9–14 355 100 (99.0–100) 804.0 (731.8–883.4) −0.28 (−1.58 to 0.79) 0.69 (0.59–0.8)
3D_M0,1,6 15–25 356 99.7 (98.4–100) 552.6 (494.1–618.0) … …
2D_M0,12 vs 2D_M0,6 2D_M0,6 − 2D_M0,12 2D_M0,6/2D_M0,12
HPV-16 2D_M0,12 9–14 339 100 (98.9–100) 1559.3 (1431.2–1699.0) 0.00 (−0.84 to 1.12) 0.78 (0.69–0.87)
2D_M0,6 9–14 455 100 (99.2–100) 1210.2 (1124.8–1302.1) … …
HPV-18 2D_M0,12 9–14 355 100 (99.0–100) 804.0 (731.8–883.4) −0.22 (−1.22 to 0.86) 0.70 (0.62–0.80)
2D_M0,6 9–14 462 99.8 (99.8–100) 562.8 (516.4–613.4) … …
Seronegative status was defined as an antibody titer lower than the assay cutoff before vaccination (assay cutoff of 8 enzyme-linked immunosorbent assay units [EU]/mL for anti–human 
papillomavirus [HPV] 16 and 7 EU/mL for anti–HPV-18 up to month 12, 19 EU/mL for anti–HPV-16 and 18 EU/ml for anti–HPV-18 from month 18 to month 36).
Two-sided 95% confidence intervals of geometric mean antibody titer ratios between groups were computed using an analysis of variance on log10 transformed titers, including vaccine 
group as a fixed effect.
Abbreviations: 2D_M0,6, 2-dose schedule administered at months 0 and 6; 2D_M0,12, 2-dose schedule administered at months 0 and 12; 3D_M0,1,6, 3-dose schedule administered at 
months 0, 1, and 6; CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; EU, enzyme-linked immunosorbent assay units; GMT, geometric mean antibody titer; HPV, human 
papillomavirus.
aNoninferiority was demonstrated if the upper limit of the 95% confidence interval for difference in seroconversion rates was less than the predefined limit of 5%.
bNoninferiority was demonstrated if the upper limit of the 95% confidence interval for the geometric mean titer ratio was less than the predefined limit of 2.
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Immunogenicity
Noninferiority Assessment
The primary objective of the study was to demonstrate the 
immunological noninferiority of the AS04-HPV-16/18 vac-
cine when administered according to the 2D_M0,6 schedule as 
compared with the 3D_M0,1,6 vaccination schedule at 1 month 
after last dose. This objective was previously reported [12].
At M36, in the ATP-I, the 2D_M0,6 schedule remained noninfe-
rior to the 3D_M0,1,6 schedule in terms of seroconversion rates 
and GMT ratios for both antigens (Table 2). Noninferiority was 
also shown for all intermediate timepoints (data not shown).
At M36, noninferiority of the 2D_M0,12 compared with the 
2D_M0,6 and the 3D_M0,1,6 schedules was demonstrated as 
well (Table 2).
Immune Responses to Human Papillomavirus Vaccine Types 16 
and 18
At M36, in each group, all initially seronegative participants in 
the ATP-I were seropositive for HPV-16 antibodies, and all but 
2 (1 in the 2D_M0,6 group and 1 in the 3D_M0,1,6 group) were 
seropositive for HPV-18 antibodies.
After a peak response at month 7, GMTs for anti–HPV-16/18 
antibodies gradually declined until month 18, and reached a 
plateau between month 18 and M36. In initially seronegative 
participants, at M36, GMTs for anti–HPV-16 and anti–HPV-
18 antibodies were 1210.2 EU/mL (95% CI  =  1124.8–1302.1) 
and 562.8 EU/mL (95% CI  =  516.4–613.4) in the 2D_M0,6 
group; 1559.3 EU/mL (95% CI  =  1431.2–1699.0) and 804.0 
EU/mL (95% CI = 731.8–883.4) in the 2D_M0,12 group; and 
1326.4 EU/mL (95% CI  =  1193.9–1473.5) and 552.6 EU/mL 
(95% CI = 494.1–618.0) in the 3D_M0,1,6 group, respectively 
(Figure 2).
At M36, all of the initially seronegative subjects in all 3 groups 
had seroconverted for both anti–HPV-16 and anti–HPV-18 nAbs 
when measured by PBNA (Figure 3). For the 2D_M0,6 group, 
GMTs at M36 were 7660.2 ED50 (95% CI = 6131.7–9569.7) for 
anti–HPV-16 nAbs and 2365.5 ED50 (95% CI = 1868.2–2995.2) 
for anti–HPV-18 nAbs; for the 2D_M0,12 group, GMTs were 
9214.3 ED50 (95% CI = 7112.3–11937.5) for anti–HPV-16 nAbs 
and 4046.4 ED50 (95% CI  =  3278.0–4994.8) for anti–HPV-18 
nAbs; for the 3D_M0,1,6 group, GMTs were 5035.0 ED50 (95% 
CI  =  3726.9–6802.0) for anti–HPV-16 nAbs and 1881.4 ED50 





































Figure  3. Anti–human papillomavirus (HPV) 16 (A) and anti–HPV-18 (B) neu-
tralizing antibody levels in initially seronegative participants at month 36 (accord-
ing-to-protocol cohort for immunogenicity). Pseudovirion-based neutralization assay 
(PBNA) cutoff: 40 ED50. Natural infection: Geometric mean titers corresponding to 
natural infection in a previous study. Geometric mean titers measured by PBNA 
were 180.1 ED50 for HPV-16 and 137.3 ED50 for HPV-18 [35]. The error bars represent 
95% confidence intervals. Abbreviations: 2D_M0,6, 2-dose schedule administered 
at months 0 and 6 (n = 88); 2D_M0,12, 2-dose schedule administered at months 0 
and 12 (n = 85); 3D_M0,1,6, 3-dose schedule administered at months 0, 1, and 6 
(n = 95); ED50, estimated dose: serum dilution giving a 50% reduction of the signal 




































Figure 2. Anti–human papillomavirus (HPV) 16 (A) and anti–HPV-18 (B) antibody 
levels in initially seronegative participants at month 36 (according-to-protocol 
cohort for immunogenicity). Natural infection: Geometric mean titers in women aged 
15–25 years who had cleared a natural infection in a previous trial (NCT00122681). 
Geometric mean titers were 29.8 and 22.7 enzyme-linked immunosorbent assay 
units (EU)/mL for HPV-16 and HPV-18 antibodies, respectively [34]. Plateau: 
Geometric mean titers at the plateau level (month 45–50 timepoint) in women aged 
15–25 years who received 3 doses of the HPV-16/18 AS04–adjuvanted vaccine at 
months 0, 1, and 6 in a previous trial (NCT00120848). Geometric mean titers were 
397.8 and 297.3 EU/mL for HPV-16 and HPV-18 antibodies, respectively [22]. The 
error bars represent 95% confidence intervals. Abbreviations: 2D_M0,6, 2-dose 
schedule administered at months 0 and 6 (n = 339); 2D_M0,12, 2-dose schedule 
administered at months 0 and 12 (n = 330); 3D_M0,1,6, 3-dose schedule adminis-
tered at months 0, 1, and 6 (n = 455); EU, enzyme-linked immunosorbent assay units; 
GMTs, geometric mean titers.
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At M36, the frequencies of HPV-16/18–specific CD4+ T cells 
and memory B cells were within similar ranges for all groups 
(Figures 4 and 5). Measurable CD4+ T-cell responses were 
detected in the 2D_M0,6, 2D_M0,12, and 3D_M0,1,6 groups 
for HPV-31 and HPV-45. No substantial HPV-16/18/31/45–
specific CD8+ T-cell responses were detected at any timepoint. 
At M36, median frequencies of HPV-31–specific B cells were 
68.0 (2D_M0,6 group), 101.0 (2D_M0,12 group) and 27.0 (3D_
M0,1,6 group), and median frequencies of HPV-45–specific 
Bcells were 59.0, 56.0, and 68.0 in these groups, respectively.
Safety
Safety results included events that occurred since the study 
started, except reactogenicity following vaccination and 
potential immune-mediated diseases, which were previously 
published [15]. Up to M36, a total of 72 participants (n = 20 
in the 2D_M0,6 group, n  =  24 in the 2D_M0,12 group, and 
n = 28 in the 3D_M0,1,6 group) reported at least 1 SAE, none 
of which were fatal. One case of systemic lupus erythematosus 
was reported by 1 subject 264  days after the first dose in the 
2D_0,12M group and was considered causally related to vacci-
nation by the investigator. The subject only received 1 dose of 
vaccine, and the event was not resolved at end of study. None 
of the other SAEs were considered to be causally related to vac-
cination by the investigator. There was 1 withdrawal due to a 
nonserious adverse event in the 2D_M0,12 group at month 12 
(the subject was diagnosed with celiac disease). There were no 
additional withdrawals due to SAEs during the course of the 
study. There was 1 withdrawal due to a nonvaccine-related SAE: 
immunoglobulin A–mediated nephritis.
Until the last follow-up visit at M36, a total of 374 partici-
pants (n = 134 in the 2D_M0,6 group, n = 87 in the 2D_M0,12 
group, and n = 153 in the 3D_M0,1,6 group) reported at least 
1 medically significant condition. A  total of 36 pregnancies 
occurred during the entire study (n = 1 in each 2-dose group, 

































































Figure  4. Human papillomavirus (HPV) 16–specific (A) and HPV-18–specific 
(B) CD4+ T-cell responses at month 36 (according-to-protocol cohort for immuno-
genicity). Boxplots show median, lower quartile, and upper quartile frequency of 
cells.Abbreviations: 2D_M0,6, 2-dose schedule administered at months 0 and 6 
(n = 75 [A] and 72 [B]); 2D_M0,12, 2-dose schedule administered at months 0 and 
12 (n = 70 [A] and 75 [B]); 3D_M0,1,6, 3-dose schedule administered at months 0, 

























































Figure  5. Human papillomavirus (HPV) 16–specific (A) and HPV-18–specific 
(B) B-cell responses at month 36 (according-to-protocol cohort for immunogenic-
ity). Boxplots show median, lower quartile, and upper quartile frequency of cells. 
Abbreviations: 2D_M0,6, 2-dose schedule administered at months 0 and 6 (n = 70 
[A] and 67 [B]); 2D_M0,12, 2-dose schedule administered at months 0 and 12 (n = 67 
[A] and 72 [B]); 3D_M0,1,6, 3-dose schedule administered at months 0, 1 and 6 
(n = 53 [A] and 54 [B]); HPV, human papillomavirus.
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resulted in live infants with no apparent congenital anomaly. 
One ectopic pregnancy, 2 elective terminations, and 1 stillbirth 
were recorded in the 3D_M0,1,6 group; none of these were con-
sidered by the investigator to be related to the vaccination.
DISCUSSION
We previously demonstrated that the AS04-HPV-16/18 vac-
cine administered as a 2-dose schedule (either 6  months or 
12 months apart) to girls aged 9–14 years elicited an immune 
response that was noninferior to the one elicited by 3 doses in 
women aged 15–25 years up to 6 months after the first dose.[15] 
These results led to the licensure of the 2-dose schedules for the 
AS04-HPV-16/18 vaccine, and subsequently, the World Health 
Organization updated its recommendation with the 2-dose 
schedule for girls aged <15 years [18]. In the current follow-up, 
we demonstrated that this observation was sustained until at 
least 36 months after the first dose. Noninferiority of a 2-dose 
HPV vaccination schedule compared with the standard 3-dose 
regimen has been reported in previous studies with the AS04-
HPV-16/18 or the 4-valent HPV vaccine [14, 17, 19–23]. In a 
recent study, Iversen and colleagues showed the noninferiority 
of 2-dose schedules in girls aged 9–14 years versus the 3-dose 
regimen with the 9-valent vaccine (Merck & Co) 4 weeks after 
the last injection [24]. However, to our knowledge, this study is 
the first large-scale, phase III, multicountry trial of HPV vac-
cines that assessed the immunogenicity of 2 different 2-dose 
schedules (2D_M0,6 and 2D_M0,12) and the persistence up to 
36  months after the first dose. The noninferiority of the 2D_
M0,12 schedule versus not only the 3D_M0,1,6 schedule and 
but also the 2D_M0,6 schedule demonstrated at the end of this 
study confirms that flexibility around the administration of the 
second dose can be considered for 2-dose vaccination.
Due to ethical and practical reasons, efficacy studies on 
HPV vaccination cannot be conducted in young girls; hence 
this study was not designed to assess efficacy endpoints such 
as high-grade cervical intraepithelial neoplasia (CIN) or per-
sistent HPV infection. In this study, the AS04-HPV-16/18 vac-
cine immunogenicity profiles were noninferior for the 2-dose 
schedules in girls compared with the 3-dose schedule in women 
aged 15–25 years, the age group in which the vaccine was shown 
to be efficacious against HPV-16/18–associated infections and 
high-grade cervical intraepithelial neoplasia in previous efficacy 
trials [25–30]. Protection against HPV infection being thought 
to be mainly antibody-mediated, it is likely that the 2-dose 
schedule of the AS04-HPV-16/18 vaccine administered to ado-
lescent girls would result in a similar level of protection to that 
previously observed in young women who received the 3-dose 
schedule. A  recent analysis of pooled efficacy data from the 
Costa Rica Vaccine Trial (CVT) and the Papilloma Trial Against 
Cancer in Young Adults (PATRICIA) suggested that 2 doses 
of the AS04-HPV-16/18 vaccine induced a similar protection 
against cervical HPV-16/18 infections as the 3-dose schedule, 
although most of the women received the vaccine only at month 
0 and month 1, which is probably not optimal [31].
The vaccine safety profile was similar between the 3 groups, 
SAEs were rarely reported (5.1%), and the overall safety pro-
file was consistent with results of the previous pooled analyses 
of HPV-16/18 AS04–adjuvanted vaccine clinical trials [32, 33]. 
One case of systemic lupus erythematosus was reported by a 
subject in the 2D_M0,12 group 264  days after the only dose 
received. The investigator considered that there was a reason-
able possibility the systemic lupus erythematosus may have 
been caused by the vaccine, although no rationale was pro-
vided for the assessment and the systemic lupus erythemato-
sus diagnosis could not be confirmed based on the information 
provided. Also, as previously described, a nonserious potential 
immune-mediated disease (VIIth nerve paralysis) reported in 
the 3-dose group was considered to have a possible causal rela-
tionship to vaccination and resolved 13 days after the first vac-
cination [15, 16]. 
A potential limitation of this study is the fact that no efficacy 
endpoints were assessed due to the age of participants (young 
girls). In addition, this study did not evaluate the 2-dose sched-
ule in females aged >15 years.
In conclusion, the immunogenicity of the HPV-16/18 AS04–
adjuvanted vaccine administered according to the 2-dose 
schedules at 6- or 12-month intervals to girls aged 9–14 years 
remained noninferior to the standard 3-dose schedule admin-
istered to young women aged 15–25 years at 36 months after 
the first administered dose. These results support the use of 
the 2-dose schedules for HPV vaccination in adolescent girls. 
Availability of both of these 2-dose schedules makes it more 
convenient for the subject, the prescriber, and mass vaccination 
campaigns.
Supplementary Data
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authors, so questions or comments should be addressed to the correspond-
ing author.
Notes
Acknowledgments. L.-M. H., C.-H. C., T. F. S., S. E., C. G., P. D., P. V. 
S., M. Hezareh, D. D., F. T., P. K., and F. S. participated in study design. T. P., 
L.-M. H., C.-H. C., R.-B. T., T. F. S., S. E., L. F., C. G., S. M., P. D., M. Horn, 
S. D. S., D. F., T. A., A. P., K. U. P., K. P., P. H., and P. V. S. acquired the data. 
L.-M. H., C.-H. C., R.-B. T., T. F. S., K. U. P., and S. E. extracted the data. 
S. E., P. V. S., and F. T. performed the analysis. T. P., L.-M. H., C.-H. C., T. F. 
S., S. E., C. G., S. M., P. D., S. D. S., D. F., B. D. M., P. V. S., D. D., F. T., K.P., 
K. U. P., and F. S. interpreted data. T. P., L.-M. H., C.-H. C., R.-B. T., T. F. 
S., S. E., L. F., C. G., S. M., P. R., P. D., T. A., A. P., K. U. P., K. P., P. H., and 
M. Horn provided study material or subject V. S. and F. T. participated in 
statistical analysis. L. F., S. D. S., and D. F. did the laboratory testing. L.-M. 
H., C.-H. C., R.-B. T., T. F. S., S. E., L. F., C. G., S. M., P. D., D. D., F. T., 
T. A., K. P., and F. S. supervised the study group. All authors had full access 
to the complete final study reports, reviewed the manuscript draft(s), and 
gave final approval to submit for publication.The authors thank all study 
Downloaded from https://academic.oup.com/jid/article-abstract/215/11/1711/3862470
by Università degli Studi di Genova user
on 12 February 2018
1718 • JID 2017:215 (1 June) • Huang et al
participants and their families and all clinical-study site personnel who con-
tributed to the conduct of this trial. Medical writing was provided by John 
Bean (John Bean Medical Writing, Halle, Belgium). The authors would like 
to thank Business & Decision Life Sciences platform for editorial assistance 
and manuscript coordination, on behalf of GSK. Thibaud André coordi-
nated manuscript development and editorial support.
Financial support. GlaxoSmithKline Biologicals SA funded the studies 
and was involved in all stages of study conduct, including analysis of the 
data. GlaxoSmithKline Biologicals SA also covered all costs associated with 
the development and publication of this article.
Potential conflicts of interest. T.  P.  received a grant through their 
respective institution from the GSK group of companies. R.  T.  received 
funding from the GSK group of companies through his institution. L.-M. 
H. received grants through his institution from the GSK group of compa-
nies and also received consultancy fees for participation in the HPV expert 
board and payment for educational presentation from the GSK group of 
companies. T. F. S.  received fees for board membership, consultancy, and 
payment for lectures, including service on speakers bureaus, from the GSK 
group of companies. S. E. received grants from the GSK group of compa-
nies, Crucell, Novartis, Pfizer, and Roche through her institution; payment 
for lectures, including service on speakers bureaus, from the GSK group 
of companies, Crucell, Novartis, and Astrazeneca; and support for travel 
to meetings for the study from the GSK group of companies. L. F. received 
support for travel to meetings for the study from the GSK group of compa-
nies. C. G. received payments for board membership and lectures, including 
service on speakers bureaus, from Sanofi Pasteur MSD, Merck, and the GSK 
group of companies. S. M. received grants through her institution from the 
GSK group of companies, Pfizer, and Sanofi Pasteur MSD; consultancy fees 
from Pfizer; and payment for lectures, including service on speakers bureaus, 
from Merck and Pfizer. P. R.  received funding through his institution for 
the conduct of the clinical trial, received support for travel to meetings for 
the study from the GSK group of companies, and holds stock option from 
the GSK group of companies. P. D. received a grant from the GSK group 
of companies through his institution for the conduct of this trial; received 
grants through his institution from Sanofi Pasteur MSD, Berna Crucell, 
Novartis, and Pfizer for the conduct of other clinical trials; received support 
for travel to meetings from the GSK group of companies; and received con-
sultancy fees for participation to advisory boards and payment for lectures, 
including service on speakers bureaus, from Pfizer and Sanofi Pasteur MSD. 
M. Horn received a grant from the GSK group of companies for the con-
duct of this study, consultancy fees from the GSK group of companies and 
Novartis, support for travel to meetings for the study from the GSK group 
of companies, payment for board membership from Novartis, and payment 
for lectures, including service on speakers bureaus, development of edu-
cational presentations, and travel, accommodation, and meeting expenses 
from the GSK group of companies, Sanofi Pasteur MSD, and Novartis. U. K. 
P. received a grant from the GSK group of companies through his institution 
for the conduct of this trial; received other grants through his institution 
from the GSK group of companies and Sanofi Pasteur MSD for the conduct 
of other clinical trials; and received personal fees from the GSK group of 
companies and Sanofi Pasteur MSD. A.  T.  received grants from the GSK 
group of companies through his institution for the conduct of this and other 
trials. P.  H.  received a grant from Medizinische Hochschule Hannover, 
Germany. S. D. S., D. F., P. S., F. T.s, D. D., N. F., and F. S. are employees of 
the GSK group of companies. M. Hezareh is a Chiltern International con-
sultant for the GSK group of companies. F. T. holds stock options from the 
GSK group of companies. D. D., N. F., and F. S. hold restricted shares/shares 
in the GSK group of companies as part of their employee remuneration. All 
other authors: No reported conflicts. All authors have submitted the ICMJE 
Form for Disclosure of Potential Conflicts of Interest. Conflicts that the edi-
tors consider relevant to the content of the manuscript have been disclosed.
References
 1. ICO Information Centre on HPV and Cancer. Human Papillomavirus and 
Related Diseases Report–World. http://hpvcentre.net/statistics/reports/XWX.pdf. 
Accessed April 10 2016.
 2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer 
statistics, 2012. CA Cancer J Clin 2015; 65:87–108.
 3. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of 
human papillomavirus infections and type-specific implications in cervical neo-
plasia. Vaccine 2008; 26 Suppl 10:K1–16.
 4. de Sanjose S, Quint WG, Alemany L, et al.; Retrospective International Survey and 
HPV Time Trends Study Group. Human papillomavirus genotype attribution in 
invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet 
Oncol 2010; 11:1048–56.
 5. Muñoz N, Bosch FX, de Sanjosé S, et al.; International Agency for Research on 
Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of 
human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 
348:518–27.
 6. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in 
invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. 
Int J Cancer 2007; 121:621–32.
 7. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between 
human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244–65.
 8. Mollers M, King AJ, Knol MJ, et al. Effectiveness of human papillomavirus vaccine 
against incident and persistent infections among young girls: results from a longi-
tudinal Dutch cohort study. Vaccine 2015; 33:2678–83.
 9. Mesher D, Panwar K, Thomas SL, Beddows S, Soldan K. Continuing reductions 
in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in 
England: an ongoing cross-sectional study. BMJ Open 2016; 6:e009915.
 10. Cameron RL, Kavanagh K, Pan J, et  al. Human papillomavirus prevalence and 
herd immunity after introduction of vaccination program, Scotland, 2009–2013. 
Emerg Infect Dis 2016; 22:56–64.
 11. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human 
papillomavirus vaccine for the prevention of cervical abnormalities: case-control 
study nested within a population based screening programme in Australia. BMJ 
2014; 348:g1458.
 12. Leval A, Herweijer E, Ploner A, et al. Quadrivalent human papillomavirus vac-
cine effectiveness: a Swedish national cohort study. J Natl Cancer Inst 2013; 
105:469–74.
 13. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) 
prevalence among young women following HPV vaccine introduction in the 
United States, National Health and Nutrition Examination Surveys, 2003–2010. J 
Infect Dis 2013; 208:385–93.
 14. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vac-
cine in younger adolescents vs 3 doses in young women: a randomized clinical 
trial. JAMA 2013; 309:1793–802.
 15. Puthanakit T, Huang LM, Chiu CH, et  al. Randomized open trial comparing 
2-dose regimens of the human papillomavirus 16/18 AS04-adjuvanted vaccine in 
girls aged 9–14 years versus a 3-dose regimen in women aged 15–25 years. J Infect 
Dis 2016; 214:525–36.
 16. Puthanakit T, Schwarz T, Esposito S, et al. Immune responses to a 2-dose schedule 
of the hpv-16/18 as04-adjuvanted vaccine in girls (9–14) versus 3 doses in women 
(15–25): a randomised trial [abstract IW 1–5]. In: EUROGIN Conference, 2013. 
http://www.eurogin.com/2013/images/pdf/EUROGIN-2013-Abstracts-Part-2.
pdf.
 17. Hernández-Ávila M, Torres-Ibarra L, Stanley M, et al. Evaluation of the immuno-
genicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: an 
epidemiological surveillance mechanism for alternate vaccination schemes. Hum 
Vaccin Immunother 2016; 12:30–8.
 18. Meeting of the Strategic Advisory Group of Experts on immunization, April 
2014—conclusions and recommendations. Wkly Epidemiol Rec 2014; 89:221–36. 
https://www.ncbi.nlm.nih.gov/pubmed/24864348.
 19. Lazcano-Ponce E, Stanley M, Muñoz N, et al. Overcoming barriers to HPV vac-
cination: non-inferiority of antibody response to human papillomavirus 16/18 
vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 
21 months. Vaccine 2014; 32:725–32.
 20. Leung TF, Liu AP, Lim FS, et al. Comparative immunogenicity and safety of human 
papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vac-
cine administered according to 2- and 3-dose schedules in girls aged 9–14 years: 
results to month 12 from a randomized trial. Hum Vaccin Immunother 2015; 
11:1689–702.
 21. Romanowski B, Schwarz TF, Ferguson L, et al. Sustained immunogenicity of the 
HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in ado-
lescent girls: five-year clinical data and modeling predictions from a randomized 
study. Hum Vaccin Immunother 2016; 12:20–9.
 22. Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of 
the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule com-
pared with the licensed 3-dose schedule: results from a randomized study. Hum 
Vaccin 2011; 7:1374–86.
Downloaded from https://academic.oup.com/jid/article-abstract/215/11/1711/3862470
by Università degli Studi di Genova user
on 12 February 2018
2-Dose Regimens of AS04-HPV-16/18 Vaccine • JID 2017:215 (1 June) • 1719
 23. Romanowski B, Schwarz T, Ferguson L, et al. Immune response to the hpv-16/18 
as04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years 
after vaccination [abstract OC 6–11]. In: EUROGIN Conference, 2013. http://
www.eurogin.com/2013/images/pdf/EUROGIN-2013-Abstracts-Part-2.pdf.
 24. Iversen OE, Miranda MJ, Ulied A, et  al. Immunogenicity of the 9-valent HPV 
vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. 
JAMA 2016; 316:2411–21.
 25. Harper DM, Franco EL, Wheeler C, et al.; GlaxoSmithKline HPV Vaccine Study 
Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infec-
tion with human papillomavirus types 16 and 18 in young women: a randomised 
controlled trial. Lancet 2004; 364:1757–65.
 26. Harper DM, Franco EL, Wheeler CM, et al.; HPV Vaccine Study group. Sustained 
efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human 
papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 
2006; 367:1247–55.
 27. Lehtinen M, Paavonen J, Wheeler CM, et  al.; HPV PATRICIA Study Group. 
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater 
cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, 
double-blind PATRICIA trial. Lancet Oncol 2012; 13:89–99.
 28. Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immu-
nogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis 
of a long-term follow-up study up to 9.4  years post-vaccination. Hum Vaccin 
Immunother 2014; 10:2147–62.
 29. Paavonen J, Naud P, Salmerón J, et  al.; HPV PATRICIA Study Group. Efficacy 
of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervi-
cal infection and precancer caused by oncogenic HPV types (PATRICIA): final 
analysis of a double-blind, randomised study in young women. Lancet 2009; 
374:301–14.
 30. Wheeler CM, Castellsagué X, Garland SM, et al.; HPV PATRICIA Study Group. Cross-
protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection 
and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study anal-
ysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:100–10.
 31. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et  al.; Costa Rica Vaccine 
Trial Study Group Authors; PATRICIA Study Group Authors; HPV PATRICIA 
Principal Investigators/Co-Principal Investigator Collaborators; GSK Vaccines 
Clinical Study Support Group. Efficacy of fewer than three doses of an HPV-16/18 
AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine 
and PATRICIA Trials. Lancet Oncol 2015; 16:775–86.
 32. Angelo MG, David MP, Zima J, et al. Pooled analysis of large and long-term safety 
data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial 
programme. Pharmacoepidemiol Drug Saf 2014; 23:466–79.
 33. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-
16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis 
of 11 clinical trials. Hum Vaccin 2009; 5:332–40.
 34. Paavonen J, Jenkins D, Bosch FX, et al.; HPV PATRICIA study group. Efficacy of 
a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection 
with human papillomavirus types 16 and 18 in young women: an interim analysis 
of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161–70.
 35. Einstein MH, Baron M, Levin MJ, et al.; HPV-010 Study Group. Comparison of 
the immunogenicity and safety of Cervarix and Gardasil human papillomavirus 
(HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin 
2009; 5:705–19.
Downloaded from https://academic.oup.com/jid/article-abstract/215/11/1711/3862470
by Università degli Studi di Genova user
on 12 February 2018
